Abstract:We have previously shown that [D-Trp(32)]NPY can competitively antagonize NPY-induced feeding in rats (Balasubramaniam et al. J. Med. Chem. 1994, 37, 811-815). This peptide, however, did not bind to SK-N-MC cells with Y-1 receptors. Since centrally truncated NPY analogs have been shown to bind Y-1 receptors, we synthesized similar analogs of [D-Trp(32)]NPY and investigated their Y-1 (SK-N-MC) and Y-2 (SK-N-BE2) receptor affinities and their properties in human erythroleukemia (HEL) cells. None of the analogs with D-Trp(32) mobilized intracellular calcium, [Ca2+](i), in HEL cells. Although Des-AA(6-24)[Aoc(6)]NPY and the corresponding D-Trp(32) analog exhibited no affinity to Y-1 receptors, Des-AA(7-24)[AoC(6),D-Trp(32)]Npy (6) exhibited weak binding. Replacing pro(5) in 6 with D-Ala to stabilize the central chain reversal, and hence the antiparallel alignment of the N- and C-terminal regions known to be important for Y-1 binding, resulted in an analog, Des-AA(7-24)[D-Ala(5),Aoc(6),D-Trp(32)]NPY (7), which exhibited moderate antagonist potency in attenuating NPY effects on cAMP and [Ca2+](i) in SK-N-MC and HEL cells, respectively. This analog also shifted the dose-response curve of NPY on blood pressure in anesthetized rats. Deletion of only the 7-17 and/or the incorporation of N-Me-Ala(5), a superior p-turn stabilizer, in 7 did not improve the Y-1 receptor affinity. Des-AA(7-24)[D-Ala(5),Gly(6),D-Trp(32)]NPY exhibited an affinity similar to that of 7, suggesting that a long spacer arm is not necessary for efficient Y-1 receptor interaction. Locking the antiparallel alignment via a 2/26 or 2/27 lactam bridge did not improve the binding. Finally, replacement of D-Ala(5) in 7 with D-Trp dramatically increased both the binding and the antagonistic potencies. Modeling based on the avian pancreatic polypeptide X-ray structure suggested that analogs which have the Nand C-terminal regions in close proximity might exhibit good binding, and that the D-Trp(32) substitution may induce a beta-turn that could be important for exhibiting antagonism. A systematic investigation has resulted in the development of relatively potent Y-1 receptor antagonists. Further structure-activity studies with these compounds and those previously reported by us and other investigators should result in the development of long-acting and receptor selective antagonists.

ChemInform Abstract: Synthesis and SAR of Selective Small Molecule Neuropeptide Y Y2 Receptor Antagonists.

Synthesis and Structure−Activity Relationships of Trisubstituted Phenyl Urea Derivatives As Neuropeptide Y5 Receptor Antagonists

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Improved Chemical and Radiochemical Synthesis of Neuropeptide Y Y2 Receptor Antagonist N-Methyl-JNJ-31020028 and Preclinical Positron Emission Tomography Studies

Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor

Structural basis for ligand recognition of the neuropeptide Y Y2 receptor

Application of the guanidine-acylguanidine bioisosteric approach to argininamide-type NPY Y₂ receptor antagonists

Structure-Based Design of High-Affinity Fluorescent Probes for the Neuropeptide Y Y1 Receptor

N-Terminus to Arginine Side-Chain Cyclization of Linear Peptidic Neuropeptide Y Y4 Receptor Ligands Results in Picomolar Binding Constants

Structure-Activity Relationship Study of the High-Affinity Neuropeptide Y4 Receptor Positive Allosteric Modulator VU0506013

An Efficient Synthesis of Selective Human NR2A Antagonist NVP-AAM077.

BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist

Structural Basis of Neuropeptide Y Signaling Through Y1 and Y2 Receptors

Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT 2 Receptor Agonist

Discovery of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists Containing an Isoxazolylpyridine Ether Scaffold That Demonstrate Antidepressant-like Activity. Part II

Antagonistic Properties of Centrally Truncated Analogs of [D-Trp(32)]npy

Discovery and SAR of Biaryl Piperidine MCH1 Receptor Antagonists Through Solid-Phase Encoded Combinatorial Synthesis

Synthesis and Structure-Activity Relationship of Imidazo[1,2-A]Benzimidazoles As Corticotropin-Releasing Factor 1 Receptor Antagonists

Synthesis, Structure–activity Relationships, and Anxiolytic Activity of 7-Aryl-6,7-dihydroimidazoimidazole Corticotropin-Releasing Factor 1 Receptor Antagonists

Neuropeptide Y (npy) Y-4 Receptor Selective Agonists Based on Npy(32-36): Development of an Anorectic Y-4 Receptor Selective Agonist with Picomolar Affinity

Identification of Novel 2-(Benzo[d]isoxazol-3-yl)-2-oxo-n-phenylacetohydrazonoyl Cyanide Analoguesas Potent EPAC Antagonists.